ClinicalTrials.Veeva

Menu

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Organon logo

Organon

Status and phase

Completed
Phase 3

Conditions

Primary Hypercholesterolemia

Treatments

Drug: Placebo
Drug: ezetimibe

Study type

Interventional

Funder types

Industry

Identifiers

NCT00867165
2008-006271-70 (EudraCT Number)
MK-0653-170 (Other Identifier)
P05522

Details and patient eligibility

About

The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children >=6 to <=10 years old with primary hypercholesterolemia. The study will also evaluate the effect of ezetimibe on total cholesterol (TC), apolipoprotein B (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides (TG). The safety of ezetimibe in this subject population will also be evaluated.

Enrollment

138 patients

Sex

All

Ages

6 to 10 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Each subject may be of either sex and of any race/ethnicity, and must be >=6 and <=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of >159mg/dL
  • Each subject's parent/guardian must be willing to give written informed consent on his/her behalf.

Exclusion criteria

Each subject must not:

  • Have known hypersensitivity or any contraindication to ezetimibe.
  • Have use of any investigational drugs within 30 days of study entry.
  • Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
  • Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing
  • Have known congenital cardiac disorder.
  • Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).
  • Be known to be human immunodeficiency virus (HIV) positive.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

138 participants in 2 patient groups, including a placebo group

Ezetimibe
Experimental group
Description:
Ezetimibe 10-mg tablet once daily for 12 weeks
Treatment:
Drug: ezetimibe
Placebo
Placebo Comparator group
Description:
Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems